Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

29.83 +0.23 (+0.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 Next >
Collegium Announces CEO Transition
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Provides 2024 Financial Guidance
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces $25 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Third Quarter 2023 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces $50 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Jefferies Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports First Quarter 2023 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report
Highlights 2022 environmental, social and governance achievements 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Provides 2023 Financial Guidance
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Appeals Court Affirms Validity of Collegium’s Belbuca® Patents
Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Piper Sandler 34th Annual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.